Combining SHOX2 and RASSF1A, the specificity and sensitivity of LungMe® were 90.0 and 89.3% in the training set and were 90.7 and 90.3% in the validation set, indicating that SHOX2 and RASSF1A gene methylation as lung cancer biomarker panel has excellent accuracy for lung cancer diagnosis (data were shown in Supplementary Table 2). This evidence concerns the gene SHOX2 and lung carcinoma.